Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06227975 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants

A Phase 1 study of Healthy Volunteers, sponsored by Celgene.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT06227975: Completed Phase 1 study of Healthy Volunteers, sponsored by Celgene.

NCT06227975 is a Phase 1 study of Healthy Volunteers that has completed, run by Celgene. The registered enrollment target is 8 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06227975, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Celgene.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate the pharmacokinetics (PK), metabolites, route of elimination, and mass balance of BMS-986368 in healthy male participants.

Conditions Studied

Interventions

  • DRUG [14C]-BMS-986368

Study Locations (1)

Wisconsin

  • Local Institution - 0001 - Madison

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2024-02-02
Est. Completion 2024-04-03
Phase Phase 1
Celgene

308 total trials

What the finished NCT06227975 record still lists

NCT06227975 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which [14C]-BMS-986368 is the first listed.

NCT06227975 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT06227975 about?

NCT06227975 is a clinical study titled "A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants". The purpose of this study is to investigate the pharmacokinetics (PK), metabolites, route of elimination, and mass balance of BMS-986368 in healthy male participants.

What is the current status of trial NCT06227975?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-02-02. Estimated completion is 2024-04-03.

What conditions does trial NCT06227975 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT06227975?

The interventions under investigation include: [14C]-BMS-986368 (DRUG).

Who is sponsoring clinical trial NCT06227975?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06227975 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06227975's enrollment target sits among peer trials

8 269th of 283 higher than 7 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06227975, the US trial registry maintained by the National Library of Medicine. NCT06227975 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.